<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03007537</url>
  </required_header>
  <id_info>
    <org_study_id>CSA-AKI2016</org_study_id>
    <nct_id>NCT03007537</nct_id>
  </id_info>
  <brief_title>The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury</brief_title>
  <official_title>The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing First Hospital, Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing First Hospital, Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To testify the prevention of Erythropoietin on cardiac surgery associated-acute kidney
      injury, and trying to provide evidence for protecting the renal function and improving the
      prognosis for patients after cardiac surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients meet the inclusion criteria and agree to sign an informed consent will be randomly
      assigned into the control group or erythropoietin group.Interventions will be applied 1
      day(24hrs) before the cardiac surgery. Blood and Urine samples will be collected after the
      surgery. By using the criterion given by KDIGO2012 and testing the biomarkers for acute
      kidney injury, we hope to find out if there is an association between erythropoietin
      administration and the occurence of acute kidney injury.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of acute kidney injury</measure>
    <time_frame>7 days</time_frame>
    <description>According to KDIGO2012</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>3 months</time_frame>
    <description>suffering from severe acute kidney injury(3.0 times baseline OR Increase in serum creatinine to ≥4.0 mg/dl (≥353.6 mmol/l)), olignuria≥24 hours or anuria≥12 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Cardiac Disease</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride 1ml, subcutaneous injection, once, applied 1day before cardiac surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythropoietin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10000 IU erythropoietin, subcutaneous injection, once, applied 1day before cardiac surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>10000 IU erythropoietin, subcutaneous injection</description>
    <arm_group_label>Erythropoietin group</arm_group_label>
    <other_name>EPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride</intervention_name>
    <description>0.9% sodium chloride 1ml, subcutaneous injection</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cardiac surgery</intervention_name>
    <description>included valve, coronary artery bypass graft or surgery for congenital heart diseases</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>Erythropoietin group</arm_group_label>
    <other_name>open-heart surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Preoperative hemoglobin＜130g/L;

          2. Surgery: valve, coronary artery bypass graft or surgery for congenital heart diseases;

          3. Volunteers with informed consent.

        Exclusion Criteria:

          1. Patients combined with infection;

          2. Patients with end-stage renal disease and undergoing renal replacement therapy

          3. Patients with the history of thromboembolism;

          4. Patients with malignant tumor and undergoing chemotherapy;

          5. Patients with unmanageable hypertension (systolic pressure&gt;200 mmHg or diastolic
             pressure&gt;110mmHg);

          6. Patients allergic to erythropoietin;

          7. Patients injected erythropoietin within 2 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Chen, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Wan, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Changchun Cao, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xin Du, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanjing First Hospital, Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaobin Ji, Doctor</last_name>
    <phone>13705174622</phone>
    <email>xbji007@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing Li, Master</last_name>
    <phone>18360868329</phone>
    <email>azalea0557@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wan, Doctor</last_name>
      <phone>18951670991</phone>
      <email>wanxin73@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ; EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007 Sep 6;357(10):965-76.</citation>
    <PMID>17804841</PMID>
  </reference>
  <reference>
    <citation>de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol. 2012 Oct 3;13:132. doi: 10.1186/1471-2369-13-132.</citation>
    <PMID>23033926</PMID>
  </reference>
  <reference>
    <citation>Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006 Nov 16;355(20):2071-84.</citation>
    <PMID>17108342</PMID>
  </reference>
  <reference>
    <citation>Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998 Aug 27;339(9):578-83.</citation>
    <PMID>9718376</PMID>
  </reference>
  <results_reference>
    <citation>Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL. Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. Crit Care. 2013 Oct 24;17(5):R254. doi: 10.1186/cc13081.</citation>
    <PMID>24156702</PMID>
  </results_reference>
  <results_reference>
    <citation>Oh SW, Chin HJ, Chae DW, Na KY. Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci. 2012 May;27(5):506-11. doi: 10.3346/jkms.2012.27.5.506. Epub 2012 Apr 25.</citation>
    <PMID>22563215</PMID>
  </results_reference>
  <results_reference>
    <citation>Tögel FE, Ahlstrom JD, Yang Y, Hu Z, Zhang P, Westenfelder C. Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models. J Am Soc Nephrol. 2016 Nov;27(11):3394-3404. Epub 2016 Mar 16.</citation>
    <PMID>26984884</PMID>
  </results_reference>
  <results_reference>
    <citation>Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009;30(3):253-60. doi: 10.1159/000223229. Epub 2009 Jun 2.</citation>
    <PMID>19494484</PMID>
  </results_reference>
  <results_reference>
    <citation>Tasanarong A, Duangchana S, Sumransurp S, Homvises B, Satdhabudha O. Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial. BMC Nephrol. 2013 Jul 5;14:136. doi: 10.1186/1471-2369-14-136.</citation>
    <PMID>23829828</PMID>
  </results_reference>
  <results_reference>
    <citation>Tie HT, Luo MZ, Lin D, Zhang M, Wan JY, Wu QC. Erythropoietin administration for prevention of cardiac surgery-associated acute kidney injury: a meta-analysis of randomized controlled trials. Eur J Cardiothorac Surg. 2015 Jul;48(1):32-9. doi: 10.1093/ejcts/ezu378. Epub 2014 Oct 13.</citation>
    <PMID>25312524</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2016</study_first_submitted>
  <study_first_submitted_qc>December 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erythropoietin</keyword>
  <keyword>Cardiac Surgery Associated-acute Kidney Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

